Lipid nanoparticles (LNPs) are a proven non-viral delivery mechanism for mRNA-based therapies, which continue to reshape modern medicine.
Key challenges in delivery remain before mRNA-based medicine can be unlocked to expand its reach.
At Axelyf, we are pairing our extensive expertise with AI-powered LNP design to accelerate mRNA therapy by designing more effective, precisely targeted, and more potent RNA delivery systems.
Advancing mRNA medicine through safer and more effective LNP delivery
‘Introducing ANNA: Turning Data into Better LNPs’
A team of experts, driven by passion and precision
Founded in Hafnarfjörður, Iceland, the Axelyf team leverages decades of expertise in pharmaceutical R&D and its global network of partners and collaborators to specialize in optimizing delivery systems for promising small molecule drugs derived from natural sources.